Navigation Links
Codexis Reports First Quarter 2011 Results
Date:5/5/2011

REDWOOD CITY, Calif., May 5, 2011 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS) today announced financial results for the first quarter ended March 31, 2011.  

First Quarter Financial Highlights:Revenue: For the first quarter of 2011, the company reported revenues of $31.0 million, an increase of 21% from $25.7 million in the first quarter of 2010.  Product revenue of $12.9 million increased 106% over the same time period driven by more than $5 million in sales of the boceprevir intermediate to be used in Merck's investigational Hepatitis C drug trade named Victrelis.  Collaborative R&D revenue of $2.7 million increased from $0.7 million in the first quarter of 2010, driven mainly by funded research for our carbon capture program.

Operating Expenses:  Research and development expenses in the first quarter of 2011 were $13.8 million, compared to $13.0 million for the first quarter of 2010.  The increase was primarily due to an increase in amortization related to intellectual property purchased from Maxygen, Inc. in the fourth quarter of 2010 and higher depreciation and stock compensation expenses. Selling, general and administrative expenses in the first quarter of 2011 increased to $9.0 million compared to $8.6 million over the same period of 2010, driven by higher stock compensation expense and higher compensation expense due to headcount increases.

Net Loss:  Net loss was ($3.5) million, or ($0.10) per share, based on 35.1 million weighted average common shares outstanding in the first quarter of 2011.   This compares to a net loss of ($1.4) million or ($0.50) per share during the first quarter of 2010.  

Adjusted EBITDA:  On a non-GAAP basis, Adjusted EBITDA decreased from $2.8 million in the first quarter of 2010 to $1.8 million in 2011. Adjusted EBITDA is calculated by adjusting net loss for ne
'/>"/>

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Former Senator Byron Dorgan Elected to Codexis Board
2. Codexis Reports Fourth Quarter and Full Year 2010 Results
3. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
4. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role
5. Codexis R&D Productivity Panels Also Used By Roche
6. Codexis Names Lori Giver VP Systems Biology
7. Codexis, Teva in Licensing Agreement Final
8. Codexis Names Vice President, Intellectual Property
9. Codexis, Arch Announce Expanded Collaboration
10. Vanda Pharmaceuticals Reports First Quarter 2011 Results
11. Reportlinker Adds Genetics Reports Bundle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... 23, 2014 On Friday, December 19, ... Omnibus and Continuing Resolution Appropriations Act of 2015, which ... to receive funding through the Congressionally Directed Medical Research ... The Hydrocephalus Association (HA), working in conjunction with its ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for Reproductive Medicine ... research in reproductive medicine. In his new role as ... board and will have a voice in furthering the mission ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... California, September 21, ChemAxon, a software solutions provider ... ) today announced an,agreement to maintain the integration ... software suite. Agilent acquired,the Kalabie ELN from Klee ... Klee and ChemAxon to Agilent and ChemAxon. ...
... catheter-related infections, REDMOND, Wash., Sept. 20 ... to enhance the biocompatibility and,performance of current ... deal with Strategic Applications Inc. (SAI), a ... infusion devices.,Healionics, deal with SAI will fully ...
... SAN DIEGO, Sept. 20 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for use ... company,s,President and CEO Theodore Schroeder will present the ... am Eastern Time (8:30 am Pacific,Time) during the ...
Cached Biology Technology:ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 2Healionics Corporation Announces Partnership to Develop and Distribute STARcuff(TM) 2Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 2
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... pluripotent stem cells were first derived in 2007, scientists have ... which are sourced in early-stage embryos. Both cell types ... body, but their origins in embryonic and adult tissue ... cell types have great potential in basic biological research and ...
... (Sept. 11, 2011) Richard Holbrooke, John Ritter, Lucille ... were all taken by the same silent killer: an ... at The University of Texas Health Science Center at ... found an association with a common genetic variant in ...
... University of Iowa researchers have found high levels of toxic ... Harbor and Ship Canal (IHSC) in East Chicago, Ind. Scientists ... is scheduled to be dredged in spring 2012 to maintain ... of southern Lake Michigan. The study, published online in ...
Cached Biology News:Study reveals critical similarity between two types of do-it-all stem cells 2Study reveals critical similarity between two types of do-it-all stem cells 3UTHealth, BCM researchers find common gene variant associated with aortic dissection 2UTHealth, BCM researchers find common gene variant associated with aortic dissection 3Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 2Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 3
...
Mouse monoclonal antibody to UGT2B10 - UDP glucuronosyltransferase 2 family, polypeptide B10...
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
Biology Products: